Duggan Robert W buys $13.0M of PLSE

Robert W. Duggan, a 10% owner and director of Pulse Biosciences (PLSE, $1.3B market cap), purchased 660,233 common shares at $19.69 per share for a total of $12,999,988 on May 11, 2026. The transaction was disclosed via two identical Form 4 filings submitted to the SEC on the same day, with EDGAR accession numbers 000143774926016190 and 000143774926016208. Concurrent with Duggan’s purchase, CEO Paul A. Laviolette also filed two Form 4 transactions for 15,000 shares each at the same $19.69 price, totaling 30,000 shares for $590,700.

Insider Context

This is the largest open-market insider purchase at PLSE in the 90-day window ending May 11, 2026. The only other insider stock sales in that period came from Chief Commercial Officer Kevin Patrick Danahy, who sold 5,000 shares on February 23, 2026 at $23.64 per share for $118,200, alongside multiple exempt stock grants to executives including Danahy and CTO Darrin Uecker, who received 100,000 restricted shares on April 3, 2026 with no associated cash outlay. Duggan, as a 10% beneficial owner, is among PLSE’s largest external shareholders, making this $13 million allocation a meaningful personal investment rather than a routine equity grant.

Cross-Reference to Analyst and Institutional Activity

The insider purchases follow two key recent market actions: a May 7, 2026 Zacks Investment Research upgrade of PLSE to a Buy rating, and the company’s May 4, 2026 Q1 2026 earnings beat, where reported EPS of -$0.27 exceeded consensus estimates of -$0.32 and revenue hit $400,000 vs a $250,000 forecast. PLSE’s analyst rating distribution has held steady at 2 Buy ratings per quarter since March 2026. As of December 31, 2025, PLSE had 81 institutional holders, representing 9.4% of its float, with 9 new positions, 31 increased positions, 30 reduced positions, and 12 closed positions in the prior quarter. No updated 13F filings have been publicly disclosed as of May 11, 2026, and shares traded at $19.08 at the time of the filings.

What This Transaction Does NOT Signal

1. This purchase does not signal an imminent formal guidance revision: no 8-K or other SEC filing containing updated financial guidance was submitted between the May 4 earnings release and the May 11 insider trades.

2. It does not reflect universal executive confidence: CCO Kevin Patrick Danahy sold 5,000 shares in February 2026 at a price higher than the insider purchase rate, and CTO Darrin Uecker has not made any open-market share purchases in 2026 to date.

3. It does not indicate a shift in near-term institutional positioning: the most recent disclosed institutional holdings data is from the end of 2025, and no Q1 2026 13F filings have been made public as of the transaction date.